Canadian grants & funding programs

NIDCR Small Research Grants for Oral Health Data Analysis and Statistical Methodology Development (R03 Clinical Trial Not Allowed)

The goal of this funding opportunity announcement is to support meritorious research projects that involve secondary statistical analyses of existing dental, oral or craniofacial database resources, or that develop needed statistical methodology for analyzing existing dental, oral or craniofacial databases.

United States

Notice of Intent to Publish a Notice of Funding Opportunity for Community-Engaged Health Equity Research in Neuroscience Initiative (R01Ôř? CT Not Allowed)

The National Institute of Neurological Disorders and Stroke (NINDS) intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) to solicit applications for research on Community-Engaged Health Equity Research in Neuroscience.Ôř?This NOFO will solicit applicationsÔř?to establish clinical trial readiness for community-driven research interventions to decrease disparities in neurological disorders in NIH-designated populations that experience health disparities (HDPs).Ôř? These clinical studies will utilize community-engaged research and collaborative, multidisciplinary teams to identify, develop and evaluate strategies to improve outcomes related to neurological disorders in HDPs and fill gaps in clinical trial readiness.. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The NOFO is expected to be published in Late Summer 2023 with an expected application due date in Fall/ Early Winter 2023.. This NOFO will utilize the R01 Clinical Trials Not Allowed activity code. Details of the planned NOFO are provided below.

United States

NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as prospective basic science studies involving human participants. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate Clinical Trials Required or Clinical Trial Optional FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

United States

Notice of Intent to Publish a Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN)

The National Center for Advancing Translational Sciences (NCATS) intends to publish aÔř?Notice of Funding Opportunity (NOFO) to solicit applications for research to advance the diagnosis, management, and treatment of rare diseases. Each Rare Diseases Clinical Research Consortium (RDCRC) will promote highly collaborative, multi-site, patient-centric, translational, and clinical research. It is strongly encouraged that the RDCRC study outcome measures include those that address unmet clinical trial readiness needs that will move the field of research forward from its current state.. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.. The NOFO is expected to be published in winter 2024, with an expected application due date in summer 2024. This NOFO will utilize the U54 activity code, which supports specialized centers through multi-project cooperative agreement awards to support research activities with substantial involvement from NIH program staff. Details of the planned NOFO are provided below.

United States

Notice of Intent to Publish a Notice of Funding Opportunity for the HEAL Initiative: KIDS Acute Pain Clinical Trials (APCT) Program (U01 Clinical Trial Required)

As part of the NIHÔř?sÔř?Helping to End Addiction Long-term (HEAL) Initiative, theÔř?Eunice Kennedy ShriverÔř?National Institute of Child Health and Human Development and participating NIH Institutes and Centers (ICs)Ôř?intend to publish a Notice of Funding Opportunity (NOFO) to support research that aligns with one of the research goals of the NIH HEAL Initiative toÔř?support new clinical trial programs and the expansion of existing programs to evaluate innovative therapies for pain management.Ôř?The HEAL KIDS (Knowledge, Innovation and Discovery Studies) PainÔř?initiativeÔř?will be comprised of interrelated programs addressing critical needs in pediatric pain research. This Notice of Intent to Publish announces plans to support the Acute Pain Clinical Trials (APCT) program, focusing on research to improve the assessment, management, and treatment of acute pain in pediatric patients in various health care settings through innovative multi-site clinical trials while integrating relevant behavioral and social influences and contexts on pain experience.Ôř?. NICHD intends to utilize a cooperative agreement activity code (U01) for this NOFO. The HEAL KIDS Pain NOFO is anticipated to be published in Summer 2023 with an expected application due date in Fall 2023. Anticipated details of the planned APCT Program are provided below.

United States

Notice of Intent to Publish a Notice of Funding Opportunity for Community-Engaged Health Equity Research in Neuroscience Initiative (R34 Clinical Trial Not Allowed)

The National Institute of Neurological Disorders and Stroke (NINDS) intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) to solicit applications for research on Community-Engaged Health Equity Research in Neuroscience.Ôř?This NOFO will solicit applicationsÔř?for planning grants to assess feasibility and/or determine best practices to conduct community-engaged health equity research in neurological disorders with populations that experience health disparities (HDPs), that, if successful, would support, enable and/or lay the groundwork for a future clinical study or trial.Ôř?In addition to posing a research question related to addressing health disparities in neurological disorders, applicants must also be filling a gap in 1) Community engagement with HDPs; and/or 2) Multidisciplinary research team expertise in neurological disorders, health disparities research and/or community engagement.Ôř?Expected outcomes would advance understanding of drivers of health disparities and barriers to neurological health equity and establish collaborative research teams, including community partners, with appropriate expertise in community engagement with HDPs, health disparities research and neurological disorders.. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.. The NOFO is expected to be published in Late Summer 2023 with an expected application due date in Fall/ Early Winter 2023.. This NOFO will utilize the R34 Clinical Trials Not Allowed activity code. The R34 Planning Grant provides support for the initial development of a research project.Ôř? Details of the planned NOFO are provided below.Ôř?

United States

Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition: High Quality Reference Genomes (HQRG) (UM1 Clinical Trial Not Allowed)

The National Human Genome Research Institute intends to renew the NHGRI Human Genome Reference Program (HGRP) to continue to improve the human pangenome reference resource. During the renewal phase there will be a new emphasis on community outreach and adoption of the resource and ensuring that it is useful to the full range of investigators working with or relying on human genetic and genomic data.. As one component of the renewal of the HGRP, NHGRI intends to publish the following RFA:. Limited Competition:Ôř?High Quality Reference Genomes (UM1 Clinical Trial Not Allowed). The purpose of this RFA is to fund a center that will produce 200 new high-quality human genome assemblies for incorporation into the human pangenome reference. As one of three components of the HGRP, this center will also include an integrated team of ethical, legal and social implications (ELSI) researchers who will be embedded in the overall HGRP This is a limited competition RFA. Only recipient organizations under RFA-HG-19-002 are eligible to apply..Ôř?

United States

Notice of Intent to Publish a Funding Opportunity for the NIH Common Fund Human Virome Program: Characterize the Human Virome in Longitudinal, Diverse Cohorts Across the Lifespan (U54 Clinical Trial Not Allowed)

The Office of Strategic Coordination (Common Fund) intends to publish a funding opportunity to support Virome Characterization Centers for the NIH Common Fund supported Human Virome Program (HVP). Ôř?More information on the HVP can be found atÔř?https://commonfund.nih.gov/humanvirome.. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and develop their approaches. The funding opportunity is expected to be published in August 2023 with an expected application due date at least 60 days after publication. No foreign applications will be allowed.. The funding opportunity will use the cooperative agreement U54 mechanism for Ôř?Specialized Center--Cooperative Agreements Ôř? Multi-component (Clinical Trial Not Allowed).Ôř? Details of the planned funding opportunity are provided below.

United States

Notice of Intent to Publish a Funding Opportunity Announcement for Clinical High Risk for Psychosis Clinical Trial Network (U01 Clinical Trial Required)

I couldn't find specific details about the grant's offerings from the provided link. Please check the website directly for accurate information on funding percentages and eligible expenses.

The purpose of this Notice is to alert the community that the National Institute of Mental Health intends to publish a Funding Opportunity Announcement (FOA) to support one or more clinical trial networks to evaluate biological and clinical outcome measures in individuals at clinical high risk (CHR) for psychosis in Proof of Principle (PoP) trials using pharmacological interventions. Unique drug development tools generated through the Accelerating Medicines PartnershipÔř? Schizophrenia (AMPÔř? SCZ) initiative will be validated in the PoP trials.. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.Ôř?The FOA is expected to be published in May 2023 with an expected application due date in FallÔř?2023.. This FOA will utilize the U01 activity code. Details of the planned FOA are provided below.

United States

Notice of Intent to Publish a Funding Opportunity Announcement for Informatics Tools for the Pangenome (U01 Clinical Trial Not Allowed)

The National Human Genome Research Institute intends to renew the NHGRI Human Genome Reference Program (HGRP) to continue to improve the human pangenome reference resource. During the renewal phase there will be a new emphasis on community outreach and adoption of the resource and ensuring that it is useful to the full range of investigators working with or relying on human genetic and genomic data.. As one component of the renewal of the HGRP, NHGRI intends to publish the following RFA:. Informatics Tools for the Pangenome (U01 Clinical Trial Not Allowed). In order to encourage utility and adoption of the HGRP pangenome reference resource, this RFA will fund a new component of the HGRP through an open competition for multiple awards. The RFA will seek applications for development of informatics tools for community use of the human pangenome reference produced by the HGRP.Ôř?. This NOFO will encourage applicants to identify the most compelling tools and applications that will enable those using genomic data to use the pangenome reference to its fullest advantage.. These tools will build on those developed by the Human Pangenome Coordination Center (see below), with the latter focusing on general computational infrastructure for pangenome use.

United States

Notice of Intent to Publish a Funding Opportunity Announcement for Data Analysis and Coordination Center for the PsychENCODE Consortium (U24 Clinical Trial Not Allowed)

The National Institute of Mental Health (NIMH) intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) to solicit applications for a Data Analysis and Coordination Center for PsychENCODE, a NIMH consortium for the discovery and characterization of human-specific non-coding functional genomic elements across brain regions, cell types, and developmental time periods and their role(s) in the molecular pathophysiology of psychiatric disorders. The Center will support the integration, harmonization, analysis, management, and dissemination of PsychENCODE Consortium data.. This Notice is being provided to allow potential applicants sufficient time to develop collaborations and responsive projects.. The NOFO is expected to be published in Summer 2023 with an expected application due date in Summer 2023.. This NOFO will utilize the U24 activity code. Details of the planned NOFO are provided below.

United States

Notice of Intent to Publish a Funding Opportunity Announcement for Human Virome Project: Developing novel and innovative tools to interrogate and annotate the human virome (U01 Clinical Trial Not Allowed)

The Office of Strategic Coordination (Common Fund) intends to publish a funding opportunity to support research and development awards for the NIH Common Fund supported Human Virome Program (HVP). Ôř?More information on the HVP can be found atÔř?https://commonfund.nih.gov/humanvirome.. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and develop their approaches. The funding opportunity is expected to be published in August 2023 with an expected application due date at least 60 days after publication. No foreign applications will be allowed.. The funding opportunity will use the cooperative agreement U01 mechanism for Ôř?Research Project Cooperative Agreement (U01 Clinical Trial Not Allowed)Ôř? Details of the planned funding opportunity are provided below.

United States

Notice of Intent to Publish a Funding Opportunity Announcement for Community Partnerships to Advance Science for Society (ComPASS): Health Equity Research Hubs (UC2 Clinical Trial Optional)

The NIH Office of the Director, Office of Strategic Coordination intends to solicit applications for theÔř?Community Partnerships to Advance Science for Society (ComPASS)Ôř?Health Equity Research Hubs (Hubs). Ôř?The Hubs will serve as a centralized research resource, providing tailored scientific, technical, and collaborative support for sustainable community engagement, research capacity building, and training to support ComPASS community-led health equity structural intervention (CHESI) projects in collaboration with the ComPASS Coordination Center (CCC).. The Hubs are one of three complementary initiatives under the ComPASS Program, which also include Community-led, Health Equity Structural Intervention projects thatÔř?intervene on structural factors that create and perpetuate health inequities and the Coordination Center that provides administration, coordination, data, and research capacity-building and training support to the CHESI projects. Ôř?Up to five Hubs are planned for funding.. This Notice is intended to allow applicants additional time to begin making arrangements to develop responsive applications.. The Notice of Funding Opportunity (NOFO) will utilize the UC2 activity code. Ôř?Details of the planned NOFO are provided below.

United States

Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition: Human Pangenome Coordinating Center (U41) Clinical Trial Not Allowed

The National Human Genome Research Institute intends to renew the NHGRI Human Genome Reference Program (HGRP) to continue to improve the human pangenome reference resource. During the renewal phase there will be a new emphasis on community outreach, adoption of the resource, and ensuring that it is useful to the full range of investigators working with or relying on human genetic and genomic data.. As one component of the renewal of the HGRP, NHGRI intends to publish the following RFA:. Limited Competition: Human Pangenome Coordinating Center (HPCC) (U41 Clinical Trial Not Allowed). The purpose of this RFA is to solicit applications to develop and implement the Human Pangenome Coordinating Center (HPCC) for the HGRP. This is a limited competition RFA. Only recipient organizations funded under RFA-HG-19-004 are eligible to apply.Ôř?The HPCC will create, improve, release, and maintain new pangenome reference versions with an emphasis on activities that will facilitate adoption by the research community.Ôř?

United States

NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)

The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.

United States

NIH Blueprint for Neuroscience Research: Tools and Technologies to Explore Nervous System Biomolecular Condensates (R21 Clinical Trial Not Allowed)

The purpose of this FOA is to support the development of innovative tools and/or technologies to monitor or manipulate biomolecular condensates (BMCs) in vivo and enable investigators to adopt these tools to answer outstanding questions in basic neuroscience. This research will transform our understanding of the mechanistic role of BMCs in human nervous system health and disease and may serve as the foundation for the development of novel BMC-based therapeutics.

United States

Notice of Intent to Publish a Funding Opportunity Announcement for A Consortium for Gut-Brain Communication in ParkinsonÔř?s Disease (U01 Clinical Trial Not Allowed)

This notice is to inform the research community that National Institute of Diabetes and Digestive and Kidney Disease (NIDDK) intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications to participate in the Gut-Brain Communication in ParkinsonÔř?s Disease (PD) Consortium (GBPDC). The goals of this initiative are:. 1) to establish a network of individual research projects and a Coordinating and Data Management Center (CDMC) focused on clinical research; 2) recruitment of sufficient patients and use of standardized protocols to collect data and biospecimens relevant to both neurology and gastroenterology research; 3) share data, biomaterials, models, reagents, resources and methods among projects in the GBPDC; and 4) make these publicly available through the CDMC.. The objective of this consortium is to accelerate research on the role of gastrointestinal (GI) symptoms and changes in gut-brain communication in the initiation and pathogenesis of ParkinsonÔř?s disease in order to facilitate development and validation of innovative early-phase GI-based diagnostic tools and biomarkers for PD. The research centers of the GBPDC will serve as sites for enrollment of PD patients and healthy age-matched controls for longitudinal studies involving the clinical assessment of relevant neurologic and GI function as well as laboratory-based studies on biological samples obtained from these patients.. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.Ôř?. The FOA is expected to be published in Spring, 2023 with an expected application due date in Fall, 2023.. This FOA will utilize the U01 activity code. Details of the planned FOA are provided below.

United States

Notice of Intent to Publish a Funding Opportunity Announcement for A Consortium for Gut-Brain Communication in ParkinsonÔř?s Disease (U24 Clinical Trial Not Allowed)

The National Institute of Diabetes and Digestive and Kidney Disease (NIDDK) intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications for a Coordinating and Data Management Center (CDMC) that will manage collaborations among the Gastroenterology Neurology Research Centers (GNRCs) that will form the Gut Brain Parkinson's Disease Consortium (GBPDC). The responsibilities of the CDMC include, but are not limited to: (1) coordination of enrollment of subjects into the study; (2) management of consortium-wide meetings and conferences, and cross-consortium collaborative activities; (3) provision of statistical and computational analysis support; and (4) establishing a central data hub for data capture, curation and management, and protocol development and registration.. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and strong responsive projects.Ôř? The FOA is expected to be published in Spring, 2023 with an expected application due date in Fall, 2023.. This FOA will utilize the U24 mechanism Ôř?Resource-Related Research ProjectsÔř?Cooperative Agreements". Details of the planned FOA are provided below.

United States

Notice of Intent to Publish a Funding Opportunity Announcement for Biotypes of CNS complications in people living with HIV (P01 Clinical Trial Not Allowed)

The National Institute of Mental Health, in collaboration with the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Drug Abuse (NIDA), intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) to solicit applications for researchÔř? toÔř?understand the heterogeneity ofÔř?central nervous system (CNS) outcomes in peopleÔř?with HIVÔř?employing quantitative assessments that are linked to psychopathology,Ôř?to identify distinct disease phenotypes, known as biotypes. .. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.Ôř?. The NOFO is expected to be published in Spring 2023 with an expected application due date in Summer 2023.. This NOFO will utilize the P01 activity code. Details of the planned NOFO are provided below.

United States

NIH Administrative Supplements to Recover Losses due to Hurricanes Fiona and Ian Under the Consolidated Appropriations Act, 2023 (Admin Supp Clinical Trial Optional)

The purpose of this funding opportunity is for investigators and institutions impacted by Hurricanes Fiona and Ian with active NIH grants to request: . 1)a 24-month extension of the current budget period, with 12-months of funding at the same funding level as the current year of the grant and/or . 2)a one-time administrative supplement of up to $150,000 in direct costs (excluding consortium facilities and administrative costs) to replace lost and/or damaged research resources; and/or. 3)up to $250,000 to replace a single item of equipment so long as that request is accompanied by well-documented support for the need to replace that item of equipment; and/or . 4)minor alternation and renovation to research facilities up to $500,000. . Supplement requests will be routed to the appropriate NIH Institutes and Centers for consideration. . The number of awards issued will depend on the number of applicants received and funneled through the review process. . Benefits of this opportunity are restricted to applicants located in a county or parish where a major disaster has been declared under the Stafford Act as a result of Hurricanes Fiona and Ian. . Grants at NIH-supported institutions impacted by Hurricanes Fiona and Ian will be eligible for both the funded extension and/or administrative supplements. If a grant has relocated or relocates prior to the award of the funded extension, the funded extension may be withdrawn.. Applications submitted in response to this announcement will be considered for funding only with funds appropriated from the Consolidated Appropriations Act, 2023 (Public Law 117-328). This opportunity does not preclude additional requests for administrative supplements on other NIH grant programs or for these mechanisms. Institutes and Centers will still consider such requests on a case-by-case basis.. These funds cannot duplicate nor overlap with reimbursement provided by FEMA, under a contract for insurance, or by self-insurance. Self-insurance is a forma

United States

NIGMS National and Regional Resources (R24 - Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) encourages applications for support of national or regional resources that will provide access to state-of-the-art facilities, equipment, technologies, research tools, software, and/or service to a substantial user base at institutions across multiple states (regional) or the country (national). These resources should already be established, although new resources formed through consolidation of multiple local or regional facilities are also eligible. They should be poised to achieve or already have achieved significant economies of scale and should be able to significantly increase access to the supported technologies or services for researchers across one or more regions or the country. Major new research and development efforts should not be included. For this FOA, a resource is defined as an activity that provides research capabilities and expertise to a large number of investigators and is available to any qualified investigator as a service. The intent is to provide access to investigators without regard to the particular biomedical focus of their research, but not to duplicate or replace resources supported by other NIH Institutes and Centers (ICs) or host institutions. Only those resources whose technical capabilities fall within the program areas supported by NIGMS will be supported. It is expected that the resource will be maintained or upgraded to current best practices, make its capability and availability known to the biomedical research community through outreach activities, and provide user training and support. Stand-alone data resources and databases are not eligible for funding through this FOA. This FOA is limited to applications requesting support for resources that have been developed through previous NIGMS funding.

United States

K01 Mentored Research Scientist Development Award

The purpose of the K01 grant program is to provide support and dedicated time for a supervised (mentored) career development experience in occupational safety and health research, leading to research independence. This grant program also is to help ensure the availability of adequate numbers of highly trained scientists and educators to address critical issues in occupational safety and health.

United States

NIH Directors Transformative Research Awards (R01 Clinical Trial Optional)

The NIH Directors Transformative Research Award Program supports individual scientists or groups of scientists proposing groundbreaking, exceptionally innovative, original, and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the nations research workforce. Individuals from diverse backgrounds, including those from underrepresented groups (see, Notice of NIH's Interest in Diversity, NOT-OD-20-031) are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications are welcome from the full spectrum of eligible institutions in all geographic locations and in all topic areas relevant to the broad mission of NIH, including, but not limited to, behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. No preliminary data are required. Projects must clearly demonstrate, based on the strength of the logic, a compelling potential to produce a major impact in a broad area of relevance to the NIH. The NIH Directors Transformative Research Award is a component of the High-Risk, High-Reward Research program of the NIH Common Fund.. Towards the objective of funding the best possible science, the Office of Strategic Coordination and the Center for Scientific Review are piloting a process for initial peer review of applications received in response to this FOA in which the identity of the investigators and institutions are withheld until the last phase of review. Instructions for anonymizing components of the application are given in Section IV and must be carefully followed. A description of the review process is given in Section V.

United States

NIH Pathway to Independence Award (Parent K99/R00 Independent Basic Experimental Studies with Humans Required)

The purpose of the NIH Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented, NIH-supported, independent investigators. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers.

United States

BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21) (Clinical Trial Not Allowed)

A central goal of the BRAIN Initiative is to understand how electrical and chemical signals code information in neural circuits and give rise to sensations, thoughts, emotions and actions. While currently available technologies can provide some understanding, they may not be sufficient to accomplish this goal. For example, non-invasive technologies are low resolution and/or provide indirect measures such as blood flow, which are imprecise; invasive technologies can provide information at the level of single neurons producing the fundamental biophysical signals, but they can only be applied to tens or hundreds of neurons, out of a total number in the human brain estimated at 85 billion. Other BRAIN FOAs seek to develop novel technology (RFA-NS-17-003) or to optimize existing technology ready for in-vivo proof-of-concept testing and collection of preliminary data (RFA-NS-17-004) for recording or manipulating neural activity on a scale that is beyond what is currently possible. This FOA seeks applications for unique and innovative technologies that are in an even earlier stage of development than that sought in other FOAs, including new and untested ideas that are in the initial stages of conceptualization. In addition to experimental approaches, the support provided under this FOA might enable calculations, simulations, computational models, or other mathematical techniques for demonstrating that the signal sources and/or measurement technologies are theoretically capable of meeting the demands of large-scale recording or manipulation of circuit activity in humans or in animal models. The support might also be used for building and testing phantoms, prototypes, in-vitro or other bench-top models in order to validate underlying theoretical assumptions in preparation for future FOAs aimed at testing in animal models.

United States

NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed)

The purpose of the NIH Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented, NIH-supported, independent investigators. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers.

United States

NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)

The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s).

United States

Value-adding Equipment Program

75% funding for value-added equipment, enhancing local food production and sustainability.

The Value-adding Equipment Program supports value-added businesses. The program helps increase local food production, and improve food security and sustainability for farms and communities.

Nova Scotia

Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) uses a R61/R33 Phased Innovation Award mechanism to support clinical research applications that are exploratory and developmental in nature and focus on understanding the neurobiological mechanisms underlying SUD, including fundamental brain function relevant to substance use. This FOA is particularly designed to support exploratory/developmental projects requiring budgets that would exceed that allowed for the R21 mechanism (Neuroscience Research on Drug Abuse (R21 Clinical Trial Optional)

United States

Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (T32)

The specific purpose of this Funding Opportunity Announcement (FOA) is to promote the development of a diverse, interdisciplinary workforce needed to conduct translational research on Alzheimer's disease and Alzheimer's-related dementias from target discovery through clinical development. This FOA will support institutional training programs for predoctoral and postdoctoral level researchers with diverse educational backgrounds (i.e., basic biology, translational and clinical research, data science). The program invites eligible institutions to develop interdisciplinary training programs that will provide trainees with the knowledge and skills in data science, disease biology, behavioral research, and traditional and emerging drug discovery disciplines necessary to conduct rigorous and cutting-edge basic, translational, and clinical research for AD/ADRD.

United States

NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Required)

The purpose of the NIH Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented, NIH-supported, independent investigators. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers.

United States

INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Clinical Research Short Course (R25 Independent Clinical Trial Not Allowed)

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome (DS). As part of the INCLUDE Project, NIH is interested in expanding and diversifying the skilled DS clinical research workforce. The intent of this Funding Opportunity Announcement (FOA) is to encourage applications that develop creative and innovative short courses to train the next generation of DS researchers in state-of-the-art clinical research skills that will improve the understanding of the co-occurring clinical features in DS and support development of new treatments for health conditions experienced by those with DS.

United States

NEI Collaborative Clinical Vision Research Project: Coordinating Center Grant (UG1 Clinical Trial Required)

The NEI uses UG1 cooperative agreement awards to support investigator-initiated large-scale clinical trials, human gene-transfer, stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials. These projects are multifaceted and of high public health significance requiring clear delineation of study organization including roles and responsibilities and require careful performance oversight and monitoring. . For purposes of this Notice of Funding Opportunity (NOFO), the proposed study must be intended to evaluate interventions aimed at screening, diagnosing, preventing, or treating vision disorders, or to compare the effectiveness of two or more established interventions.. The NEI UG1-supported studies are typically funded as a group of single-component companion grant awards including the Chairs Grant, the Coordinating Center, and Resource Centers, when appropriate.. Specifically, this NOFO encourages applications for the Coordinating Center grant, which provides details of the Coordinating Center's responsibilities and operations.

United States

Innovative Pilot Mental Health Services Research Not Involving Clinical Trials (R34 Clinical Trial Not Allowed)

Reissue of PAR-19-189. The purpose of this funding announcement is to encourage pilot research that is not an immediate precursor to testing a service intervention but is consistent with NIMH priorities for services research. While NIMH now requires use of an experimental therapeutics model for all intervention studies, there is recognition that some mission-relevant areas of services research do not involve clinical trials.

United States

Instrumentation Grant Program for Resource-Limited Institutions (S10 - Clinical Trial Not Allowed)

The Instrumentation Grant Program for Resource-Limited Institutions supports the purchase of state-of-the-art scientific instruments to enhance the research and educational missions of resource-limited institutions. Requested instruments may support biomedical research and education in basic, translational, biomedically-related behavioral or clinical fields.

United States

Intervention Research to Improve Native American Health (R01 Clinical Trial Optional)

The purpose of this funding opportunity announcement (FOA) is to support research on interventions to improve health in Native American (NA) populations. This includes 1) etiologic research, where there is a significant gap in knowledge, that will directly inform intervention development or adaptations, 2) research that develops, adapts, or tests the efficacy or effectiveness of health promotion and disease prevention interventions, 3) research that tests culturally informed treatment or recovery interventions and 4) where a sufficient body of knowledge on intervention efficacy exists, research on dissemination and implementation that develops and tests strategies to overcome barriers to the adoption, integration, scale-up, and sustainability of effective interventions. Existing data suggest that significant acute and chronic disease inequities exist for NA populations. Concurrently, NA populations experience unique sociopolitical, historical, and environmental stressors and risks that may exacerbate health conditions and/or impact the effectiveness of existing solutions to address the conditions. They also possess unique strengths and resiliencies that can mitigate stressors or inform intervention strategies. Through this initiative, intervention and related research is sought to build upon community knowledge, resources, and resilience to test science-based, culturally appropriate solutions to reduce morbidity and mortality through identification and remediation of precursors to diseases and disorders and through culturally informed treatment. Interventions should be designed with a consideration for sustainability within the communities where they are tested, and have the flexibility to be readily adapted, disseminated, and scaled up to other communities where culturally appropriate. For the purposes of this FOA, Native Americans include the following populations: Alaska Natives, American Indians (whose ancestral lands fall at least partially within the U.S. ma

United States

Bioénergies – Analysis

75% funding for bioenergy project analysis, implementation, and simplified procedures.

The Bioénergies Project Analysis provides financial assistance for determining potential measures for converting fossil fuels to bioenergy, and to determine the cost of implementing them.

Quebec

NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)

This FOA invites applications for investigator-initiated, high-risk multi-center clinical trials involving m?o?r?e? ?t?h?a?n? ?o?n?e? clinical center. Proposed trials should be hypothesis-driven, have the potential to change clinical practice and/or public health, and focus on a disease relevant to the mission of NIDDK. Planning activities must be completed prior to submission and are not permitted under this FOA. Applicants who require a planning phase may first apply for an implementation planning cooperative agreement (U34; see TEMP9971).Consultation with NIDDK Scientific/Research staff is strongly encouraged prior to the submission of either a U34 or U01 application.

United States

Fonds de développement de l'économie sociale

Up to 50% funding for technology, professional fees, and capital expenses.

The FDÉS provides subsidies between $5,000 and $50,000 to support social economy initiatives in Montréal.

Quebec

Integrative Research to Understand the Impact of Sex Differences on the Molecular Determinants of AD Risk and Responsiveness to Treatment (U01 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) invites applications that employ integrative experimental and analytical approaches engaging basic and translational/clinical research aimed at developing a comprehensive understanding of the impact of sex differences on the trajectories of brain aging and disease, phenotypes of AD and AD-related dementias (ADRD) risk, individualized prevention, and responsiveness to pharmacologic and non-pharmacologic interventions. To this end, the central goal of this initiative is to develop robust research programs that will explore how genes, environment, and host factors such as hormonal status (gonadal and brain-derived) interact at various levels of biologic complexity (i.e., cell, tissue, organs/organ systems, and populations) to produce heterogeneous phenotypes of disease risk and responsiveness to prevention/therapy in AD/ADRD.

United States

Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R01 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to support basic research that elucidates mechanisms by which the human microbiome inhibit or enhance anti-tumor immune responses, and to identify potential novel molecular targets for cancer prevention strategies. Applications should be focused on delineating how host interactions with specific microbes (or consortia) or their metabolites targets immune responses that enhance or prevent inflammation-associated or sporadic tumor formation. Concentration, timing, and duration of administered beneficial microbes may alter its effectiveness and thus those parameters should be rigorously addressed in the application.

United States

Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required)

This is a reissue of RFA-MH-18-704: Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required). As part of NIMH's clinical trials pipeline, this FOA encourages pilot research developing and testing novel psychosocial interventions and/or targets. Consistent with NIMH's emphasis on the experimental therapeutics approach to intervention development, it intends to speed the translation of emergent research in basic, behavioral, cognitive, affect, and neuropsychological science into preventative or therapeutic interventions. This RFA will provide up to two years of support for evaluation of target engagement and establishment of intervention parameters, and up to three years of support to replicate target engagement from prior studies and to test the association between target engagement and change in clinical outcome(s).

United States

Cancer Research Education Grants Program - Curriculum or Methods Development (R25 Clinical Trial Not Allowed)

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Curriculum or Methods Development. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients.

United States

NIDCR Dual Degree Dentist Scientist Predoctoral to Postdoctoral Transition Award (F99/K00 Independent Clinical Trial Not Allowed)

The purpose of the NIDCR Dual Degree Dentist Scientist Predoctoral to Postdoctoral Transition Award (F99/K00) is to provide support and mentorship to outstanding students enrolled in integrated dual degree dental (DDS/DMD) and PhD programs over the transition from predoctoral student to postdoctoral scholar. This phased award program will facilitate completion of predoctoral dual degree dentist scientist training (F99) and progression to mentored postdoctoral positions in dental, oral and craniofacial research (K00). It is anticipated that successful completion of this phased award program will enable dentist scientists to progress in their research careers. This Funding Opportunity Announcement (FOA) does not allow prospective fellows to propose to lead an independent clinical trial, but does allow prospective fellows to propose research experience in a clinical trial led by a sponsor or co-sponsor.

United States

NIDCR Small Grant Program for New Investigators (R03 Clinical Trial Not Allowed)

The NIDCR Small Grant Program for New Investigators (R03) supports basic and clinical research conducted by scientists who are in the early stages of establishing an independent research career in oral, dental and craniofacial research. This program supports pilot or feasibility studies and developmental research projects with the intention of obtaining sufficient preliminary data for a subsequent investigator-initiated Research Project Grant (R01) or equivalent application.

United States

Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)

This is a reissue of RFA-MH-18-703: Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required). NIMH requires an experimental therapeutics approach for the development and testing of therapeutic interventions, in which studies both evaluate the clinical effect of an intervention and generate information about the mechanisms underlying a disorder or an intervention response. As part of NIMHs Clinical Trial Pipeline, this FOA encourages early stage testing of pharmacologic interventions with novel mechanisms of actions or device-based interventions. More specifically, this FOA is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a dose-dependent neurophysiological/clinical/behavioral effect.

United States

Cancer Adoptive Cellular Therapy Network (Can-ACT) for Pediatric Cancers (UG3/UH3 Clinical Trial Required)

The National Cancer Institute (NCI) intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) soliciting UG3/UH3 applications for the Cancer Adoptive Cellular Therapy (Can-ACT) Network. The goal of this collaborative research network will be to stimulate the conduct of early adoptive cellular therapy clinical trials for adult and pediatric solid tumors. The emphasis is on accelerating the advancement of new cell therapy strategies into clinical testing through novel and collaborative approaches to preclinical testing and translational studies. Can-ACT will support multi-investigator teams with the relevant expertise, assembled to bring new cell therapy products to the clinic.

United States

Cancer Adoptive Cellular Therapy Network (Can-ACT) for Adult Cancers (UG3/UH3 Clinical Trial Required)

The National Cancer Institute (NCI) intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) soliciting UG3/UH3 applications for the Cancer Adoptive Cellular Therapy (Can-ACT) Network. The goal of this collaborative research network will be to stimulate the conduct of early adoptive cellular therapy clinical trials for adult and pediatric solid tumors. The emphasis is on accelerating the advancement of new cell therapy strategies into clinical testing through novel and collaborative approaches to preclinical testing and translational studies. Can-ACT will support multi-investigator teams with the relevant expertise, assembled to bring new cell therapy products to the clinic.

United States